BACKGROUND: Thymic carcinoma is a very rarely encountered neoplasm and no optimal
chemotherapeutic regimen has been established yet. METHODS: The records of previously …

In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel
(CbP) showed promising efficacy in advanced TC when compared with anthracycline-based …

Objective Thymic carcinoma is a rare cancer of the thymus, different from thymoma in
respect of its malignant nature, and no standard chemotherapy for this cancer has been …

Introduction: Thymic carcinoma is a rare epithelial neoplasm that tends to be aggressive and
metastasize widely. The optimal chemotherapy for unresectable advanced thymic carcinoma …

BACKGROUND: Thymic carcinoma is a rare, malignant mediastinal tumor that is definitively
distinguished from thymoma by its wide extensiveness and poor prognosis. At present …

BACKGROUND Thymic carcinoma is a rare neoplasm that often disseminates or
metastasizes. The role of chemotherapy in treating this malignancy is unclear. The purpose …

Background The prognostic factors and the efficacy of first‐line chemotherapy remain
unclear in patients with advanced thymic carcinoma. Materials and Methods We conducted …

Background: Optimal chemotherapeutic regimen in thymic carcinoma remains uncertain and
the efficacy of second line chemotherapy has not been established either. Patients and …

Objectives: The aim of this study is to retrospectively evaluate the role of several therapies,
mainly chemotherapy, for thymic carcinoma (TC). Methods: From July 1973 to July 2005, 25 …

BACKGROUND: The clinical characteristics and prognostic factors of thymic carcinoma have
not been investigated in detail because of its rarity. The aim of this study was to elucidate the …